Rhumbline Advisers Agios Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 94,223 shares of AGIO stock, worth $5.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,223
Previous 101,180 6.88%
Holding current value
$5.15 Million
Previous $4.36 Million 4.03%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$41.19 - $49.72 $286,558 - $345,902
-6,957 Reduced 6.88%
94,223 $4.19 Million
Q2 2024

Aug 01, 2024
SELL
$27.55 - $48.83 $26,723 - $47,365
-970 Reduced 0.95%
101,180 $4.36 Million
Q1 2024

May 09, 2024
BUY
$21.32 - $34.81 $35,220 - $57,506
1,652 Added 1.64%
102,150 $2.99 Million
Q4 2023

Feb 08, 2024
SELL
$19.97 - $24.53 $32,431 - $39,836
-1,624 Reduced 1.59%
100,498 $2.24 Million
Q3 2023

Nov 09, 2023
BUY
$24.36 - $28.18 $30,206 - $34,943
1,240 Added 1.23%
102,122 $2.53 Million
Q2 2023

Aug 08, 2023
BUY
$21.38 - $29.19 $202,618 - $276,633
9,477 Added 10.37%
100,882 $2.86 Million
Q1 2023

May 11, 2023
BUY
$21.74 - $30.93 $46,458 - $66,097
2,137 Added 2.39%
91,405 $2.1 Million
Q4 2022

Feb 14, 2023
BUY
$24.81 - $31.52 $57,608 - $73,189
2,322 Added 2.67%
89,268 $2.51 Million
Q3 2022

Nov 10, 2022
BUY
$19.51 - $34.14 $103,227 - $180,634
5,291 Added 6.48%
86,946 $2.46 Million
Q2 2022

Aug 11, 2022
BUY
$17.06 - $31.42 $105,754 - $194,772
6,199 Added 8.22%
81,655 $1.81 Million
Q1 2022

May 12, 2022
SELL
$26.68 - $34.81 $168,324 - $219,616
-6,309 Reduced 7.72%
75,456 $2.2 Million
Q4 2021

Feb 10, 2022
SELL
$29.58 - $49.78 $125,389 - $211,017
-4,239 Reduced 4.93%
81,765 $2.69 Million
Q3 2021

Nov 12, 2021
SELL
$41.92 - $58.18 $106,686 - $148,068
-2,545 Reduced 2.87%
86,004 $3.97 Million
Q2 2021

Aug 05, 2021
BUY
$52.06 - $61.27 $1.01 Million - $1.18 Million
19,331 Added 27.93%
88,549 $4.88 Million
Q1 2021

May 06, 2021
SELL
$44.23 - $57.5 $82,533 - $107,295
-1,866 Reduced 2.63%
69,218 $3.57 Million
Q4 2020

Feb 10, 2021
BUY
$33.21 - $46.54 $113,910 - $159,632
3,430 Added 5.07%
71,084 $3.08 Million
Q3 2020

Nov 12, 2020
SELL
$33.87 - $55.93 $72,109 - $119,074
-2,129 Reduced 3.05%
67,654 $2.37 Million
Q2 2020

Aug 13, 2020
BUY
$34.45 - $53.48 $203,806 - $316,387
5,916 Added 9.26%
69,783 $3.73 Million
Q1 2020

May 06, 2020
BUY
$31.52 - $53.81 $481,657 - $822,270
15,281 Added 31.45%
63,867 $2.27 Million
Q4 2019

Feb 05, 2020
BUY
$30.08 - $50.59 $122,906 - $206,710
4,086 Added 9.18%
48,586 $2.32 Million
Q3 2019

Oct 23, 2019
BUY
$32.4 - $49.58 $44,323 - $67,825
1,368 Added 3.17%
44,500 $1.44 Million
Q2 2019

Aug 14, 2019
SELL
$46.17 - $68.1 $343,089 - $506,051
-7,431 Reduced 14.7%
43,132 $2.15 Million
Q1 2019

May 01, 2019
SELL
$45.92 - $67.67 $11,250 - $16,579
-245 Reduced 0.48%
50,563 $3.41 Million
Q4 2018

Jan 31, 2019
SELL
$42.73 - $76.53 $77,255 - $138,366
-1,808 Reduced 3.44%
50,808 $2.34 Million
Q3 2018

Nov 07, 2018
SELL
$71.67 - $91.95 $53,465 - $68,594
-746 Reduced 1.4%
52,616 $4.06 Million
Q2 2018

Aug 06, 2018
BUY
$73.22 - $99.55 $235,109 - $319,655
3,211 Added 6.4%
53,362 $4.5 Million
Q1 2018

May 02, 2018
BUY
$59.83 - $86.53 $300,885 - $435,159
5,029 Added 11.15%
50,151 $4.1 Million
Q4 2017

Feb 09, 2018
SELL
$52.12 - $72.33 $34,555 - $47,954
-663 Reduced 1.45%
45,122 $2.58 Million
Q3 2017

Nov 06, 2017
BUY
$54.89 - $67.12 $2.51 Million - $3.07 Million
45,785
45,785 $3.06 Million

Others Institutions Holding AGIO

# of Institutions
232
Shares Held
58.1M
Call Options Held
403K
Put Options Held
469K
View Full List

About AGIOS PHARMACEUTICALS, INC.

AGIO Quotes by TradingView
  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.99B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email